Macrolides and bronchiectasis: clinical benefit with a resistance price

Editorial

J Stuart Elborn et al. JAMA. 2013.

. 2013 Mar 27;309(12):1295-6.

doi: 10.1001/jama.2013.2780.

No abstract available

Comment on

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Altenburg J, et al. JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937. JAMA. 2013. PMID: 23532241 Clinical Trial.
Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Serisier DJ, et al. JAMA. 2013 Mar 27;309(12):1260-7. doi: 10.1001/jama.2013.2290. JAMA. 2013. PMID: 23532242 Clinical Trial.